SCHEMBL7547494

SCHEMBL7547494

c1ccc(C(CC2=NCCN2)c2nccc3ccccc23)nc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 11/20 0.50
TAAR1 Q96RJ0 5/20 0.46
LMNA P02545 3/20 0.46
CYP2D6 P10635 3/20 0.46
ADRA1A P35348 3/20 0.46
MAPK1 P28482 2/20 0.46
ADRA2A P08913 2/20 0.46
ADRA2B P18089 2/20 0.46
ADRA2C P18825 2/20 0.46
HTR1A P08908 1/20 0.46
MAPT P10636 1/20 0.46
OPRM1 P35372 1/20 0.46
MAOA P21397 5/20 0.44
MAOB P27338 5/20 0.44
ADRA1B P35368 2/20 0.40
CYP1A2 P05177 1/20 0.40
TSHR P16473 1/20 0.40
ADRA1D P25100 1/20 0.40
NFKB1 P19838 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7550085 0.84 NISCH (0.51) NISCHTAAR1LMNACYP2D6ADRA1A
SCHEMBL7548321 0.83 NISCH (0.66) NISCHTAAR1LMNACYP2D6ADRA1A
Midaglizole SCHEMBL30029057 0.79 NISCH (0.74) NISCHTAAR1LMNACYP2D6ADRA1A
Midaglizole SCHEMBL114554 0.79 NISCH (0.74) NISCHTAAR1LMNACYP2D6ADRA1A
SCHEMBL9588018 0.79 NISCH (0.48) NISCHTAAR1LMNACYP2D6ADRA1A
Midaglizole SCHEMBL752697 0.78 NISCH (0.72) NISCHTAAR1LMNACYP2D6ADRA1A
Midaglizole SCHEMBL9403180 0.78 NISCH (0.72) NISCHTAAR1LMNACYP2D6ADRA1A
SCHEMBL7547444 0.77 NISCH (0.51) NISCHTAAR1LMNACYP2D6ADRA1A
SCHEMBL7547291 0.76 NISCH (0.48) NISCHTAAR1LMNACYP2D6ADRA1A
SCHEMBL9588013 0.75 NISCH (0.52) NISCHTAAR1LMNACYP2D6ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020132812-A1 Oral hypoglycaemic agents NOVO NORDISK A/S (DK) 2002-09-19 US claimed
US-20020132812-A1 Oral hypoglycaemic agents NOVO NORDISK A/S (DK) 2002-09-19 US disclosed
WO-2002038559-A1 1,3-DIAZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS ORAL HYPOGLYCAEMIC AGENTS NOVO NORDISK A/S (DK) 2002-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020132812-A1 Oral hypoglycaemic agents SLC5A2, GPR119, SLC5A1 NISCH 448/4885TAAR1 4329/4885LMNA 4855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.